Carlsmed Reports Strong Preliminary Q4 Revenue Growth of 61% and Full-Year 2025 Revenue Growth of 86%

summarizeSummary

Carlsmed, Inc. announced robust preliminary and unaudited revenue for Q4 and full-year 2025, with significant growth driven by increased surgeon adoption of its aprevo® platform.

check_boxKey Events

• Preliminary Q4 2025 Revenue

  Reported approximately $15.2 million in revenue for the fourth quarter of 2025, marking a 61% increase compared to Q4 2024.

• Preliminary Full Year 2025 Revenue

  Announced approximately $50.5 million in revenue for the full year 2025, an 86% increase compared to full year 2024.

• Surgeon User Growth

  Added 101 new surgeon users in 2025, representing a 61% increase in the total surgeon user base over the prior year.

• Product Expansion

  Highlighted the recent launch of aprevo® cervical, a patient-specific cervical solution, with encouraging early surgeon feedback.

auto_awesomeAnalysis

The strong preliminary revenue figures, showing 61% growth in Q4 2025 and 86% growth for the full year 2025, indicate significant commercial momentum for Carlsmed. The substantial increase in surgeon users for its aprevo® platform underscores successful product adoption and market penetration. While these results are unaudited and preliminary, the high growth rates suggest a positive trajectory for the company's AI-enabled personalized spine surgery solutions, potentially improving investor confidence ahead of full financial reporting.